[
  {
    "ts": "2025-10-29T20:01:00+00:00",
    "headline": "AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS",
    "summary": "Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.",
    "url": "https://finance.yahoo.com/news/amgen-announces-webcast-2025-third-200100487.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "697b5d1c-1a92-3587-bedd-60ffd524af26",
      "content": {
        "id": "697b5d1c-1a92-3587-bedd-60ffd524af26",
        "contentType": "STORY",
        "title": "AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS",
        "description": "",
        "summary": "Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.",
        "pubDate": "2025-10-29T20:01:00Z",
        "displayTime": "2025-10-29T20:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d",
          "originalWidth": 400,
          "originalHeight": 98,
          "caption": "Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9xF64eSNrBTdXVSUBRIisA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d.cf.webp",
              "width": 400,
              "height": 98,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LmrL8PQB2Q2cD.YsureBSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-announces-webcast-2025-third-200100487.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-announces-webcast-2025-third-200100487.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T19:08:38+00:00",
    "headline": "Trump Administration Eases Approval Process for Biosimilar Drugs",
    "summary": "The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs.  Under the new draft guidance, FDA would no longer require all biosimilar manufacturers to run clinical trials of their drugs as a condition of approval.  Instead, the FDA says it will look at analytical studies that can show whether or not the biosimilar matches the branded drug it seeks to copy.",
    "url": "https://www.barrons.com/livecoverage/government-shutdown-news-today-10292025/card/trump-administration-eases-approval-process-for-biosimilar-drugs-wDZTExla2qy5H8oN9FGJ?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "e03f723c-fd6c-3ede-985b-9165072b575e",
      "content": {
        "id": "e03f723c-fd6c-3ede-985b-9165072b575e",
        "contentType": "STORY",
        "title": "Trump Administration Eases Approval Process for Biosimilar Drugs",
        "description": "",
        "summary": "The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs.  Under the new draft guidance, FDA would no longer require all biosimilar manufacturers to run clinical trials of their drugs as a condition of approval.  Instead, the FDA says it will look at analytical studies that can show whether or not the biosimilar matches the branded drug it seeks to copy.",
        "pubDate": "2025-10-29T19:08:38Z",
        "displayTime": "2025-10-29T19:08:38Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e03f723c-fd6c-3ede-985b-9165072b575e/trump-administration-eases.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/593c909ab20952b1324405ca04687b39",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A6XlvkTEcrBqwpBMgV5hOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/593c909ab20952b1324405ca04687b39.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8isx0RvslcXdn5QLmx.EZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/593c909ab20952b1324405ca04687b39.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/livecoverage/government-shutdown-news-today-10292025/card/trump-administration-eases-approval-process-for-biosimilar-drugs-wDZTExla2qy5H8oN9FGJ?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "TEVA"
            },
            {
              "symbol": "TEVJF"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T15:27:00+00:00",
    "headline": "Amgen's Q3 Earnings in the Cards: Here's What to Expect",
    "summary": "Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.",
    "url": "https://finance.yahoo.com/news/amgens-q3-earnings-cards-heres-152700999.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d15d88b9-1c51-3f7a-8647-4e608b6133ab",
      "content": {
        "id": "d15d88b9-1c51-3f7a-8647-4e608b6133ab",
        "contentType": "STORY",
        "title": "Amgen's Q3 Earnings in the Cards: Here's What to Expect",
        "description": "",
        "summary": "Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.",
        "pubDate": "2025-10-29T15:27:00Z",
        "displayTime": "2025-10-29T15:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7bc8bbeae2e0a87a69be234f543981cd",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cgmrsy.RXPZzY7yMaDwZPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7bc8bbeae2e0a87a69be234f543981cd.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HTl0ikZ844wasPEHHtWO1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7bc8bbeae2e0a87a69be234f543981cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgens-q3-earnings-cards-heres-152700999.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgens-q3-earnings-cards-heres-152700999.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T14:00:05+00:00",
    "headline": "Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for",
    "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/analysts-estimate-acadia-pharmaceuticals-acad-140005640.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4f1ab76f-201d-36db-84ec-d6b36eddc39f",
      "content": {
        "id": "4f1ab76f-201d-36db-84ec-d6b36eddc39f",
        "contentType": "STORY",
        "title": "Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for",
        "description": "",
        "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2025-10-29T14:00:05Z",
        "displayTime": "2025-10-29T14:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wrLAPGGJOM4LTlpriDsibA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KPws6ZxoY5._RUBc.aqcuQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-estimate-acadia-pharmaceuticals-acad-140005640.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-estimate-acadia-pharmaceuticals-acad-140005640.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ACAD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]